Median Technologies Announces 2022 Revenue of €23.8 Million, up 16%, and an Order Backlog of €60.8 Million
2023年1月20日 - 01:45AM
ビジネスワイヤ(英語)
- Revenue of €23.8 million as of December 31, 2022, up 16% versus
2021 (€20.5 million).
- Order backlog at €60.8 million as of December 31, 2022.
- Cash and cash equivalents of €21.5 million as of December 31,
2022.
Regulatory News:
Median Technologies (ALMDT:PA) announces its revenue level for
the full year 2022.
“In 2022, revenue generated by the iCRO business continued to
grow in double digits. Our new offer Imaging Lab, which uses
Artificial Intelligence and data mining technologies developed by
the iBiopsy® division, received a very warm welcome at the ASCO
conference in May 2022. Imaging Lab generates significant interest
from major pharmaceutical companies by enabling to deeply exploit
imaging data from their clinical trials and the roll out
development programs for new biomarkers,” highlights Fredrik Brag,
CEO and founder of Median Technologies. “After announcing
outstanding results from the detection-characterization combination
of our iBiopsy® LCS CADe/CADx Software as Medical Device in March
2022, we initiated discussions with the FDA with a view to
obtaining regulatory and marketing approval in the US for our SaMD
during the first half of 2024. Progress with the FDA is going ahead
according to the schedule we planned. At end-2022, we began
collecting the associated images and clinical data that are to be
used in our pivotal study”, adds Fredrik Brag.
iBiopsy®: clear progress in the iBiopsy® Lung Cancer
Screening clinical development plan
In 2022, the Company announced it had completed the development
of its iBiopsy® Lung Cancer Screening CADe/CADx1 Software as
Medical Device (SaMD) based on artificial intelligence and machine
learning technologies. Median’s iBiopsy® LCS CADe/CADx SaMD reached
outstanding performances (press release of March 22, 2022)
calculated across a cohort of 1,760 patients, with a sensitivity2
of 94.7% for a specificity3 of 93.3%.
During 2022, Median also initiated discussions with the FDA
(press releases of March 3, 2022, and May 5, 2022), to prepare the
application for regulatory and marketing approval for its iBiopsy®
LCS CADe/CADx SaMD in the US during the first half of 2024. At the
same time, the company expects to obtain CE marking for its
iBiopsy® SaMD during the second half of 2024.
The collection of images and retrospective data to be used in
the iBiopsy® LCS CADe/CADx pivotal study started at the end of
2022, as did recruitment of readers.
iCRO: further double-digit growth in revenue and extension of
imaging services portfolio for biopharmaceutical companies with
Imaging Lab
In 2022, Median Technologies’ iCRO4 business, which provides
services for image management in oncology trials to the
biopharmaceutical industry worldwide, continued its double-digit
growth.
As of December 31, 2022, Median Technologies’ revenue was €23.8
million, a 16% increase compared to the 2021 level. Q4 2022 revenue
stood at €5.1 million. The company’s revenue is generated entirely
by the iCRO division’s commercial activity.
From May 2022 onwards, the iCRO division leveraged the
Artificial Intelligence and data mining technologies developed by
the iBiopsy® division. iCRO is rounding out its portfolio of
services for the pharmaceutical industry with the Imaging Lab
offering. Imaging Lab enables the company's customers to deeply
exploit imaging data from their clinical trials, and to establish
research collaborations for the identification of new biomarkers.
Imaging Lab will provide new answers in four of the areas that
determine the success of clinical programs: selection of patients
included in trials, especially inclusion of patients diagnosed at
early stages, prediction of response to therapy based on imaging,
measurement of disease progression and development of imaging
companion diagnostics. The Imaging Lab offer was launched during
the 2022 American Society of Clinical Oncology (ASCO) conference in
Chicago, US.
The order backlog5 stood at €60.8 million on December 31, 2022,
up €2.8 million relative to December 31, 2021.
Cash and cash equivalents
As of December 31, 2022, cash and cash equivalents stood at
€21.5 million, compared to €39 million as of December 31, 2021.
Next financial publication April 20, 2023,
after the close of trading: 2022 annual results and Q1 2023
performance
Disclaimer: The preliminary figures set forth above are based on
management’s initial review of the Company’s operations for the
period ending December 31st, 2022 and are subject to revision based
upon the finalization of the limited review conducted on the full
year financial statements by the Group's statutory auditors. Actual
results may differ materially from these preliminary figures as a
result of the completion of H1 closing procedures, final
adjustments and other developments arising between now and the time
that the Company’s financial results are finalized, and such
changes could be material. In addition, these preliminary figures
are not a comprehensive statement of the Company’s financial
results for 2022, should not be viewed as a substitute for
condensed interim financial statements prepared in accordance with
generally accepted accounting principles, and are not necessarily
indicative of the Company’s results for any future period.
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We harness the power of medical images by using the most
advanced Artificial Intelligence technologies, to increase the
accuracy of diagnosis and treatment of many cancers and other
metabolic diseases at their earliest stages and provide insights
into novel therapies for patients. Our iCRO solutions for medical
image analysis and management in oncology trials and iBiopsy®, our
AI-powered software as medical device help biopharmaceutical
companies and clinicians to bring new treatments and diagnose
patients earlier and more accurately. This is how we are helping to
create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a
subsidiary in the US and another one in Shanghai, Median has
received the label “Innovative company” by the BPI and is listed on
Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median
is eligible for the French SME equity savings plan scheme
(PEA-PME), is part of the Enternext® PEA-PME 150 index and has been
awarded the Euronext European Rising Tech label. For more
information: www.mediantechnologies.com
1 A radiological CADe device is “intended to identify, mark,
highlight or otherwise direct attention to portions of an image
that may reveal abnormalities during interpretation of images by
the clinician.” A CADx device is “intended to provide information
beyond identifying abnormalities, such as an assessment of
disease.” – Source FDA 2 Sensitivity is the ability to correctly
generate positive results for cancer patients. 3 Specificity is the
ability to correctly generate negative results for non-cancer
patients. 4 Imaging Contract Research Organization 5 The order
backlog is the sum of orders received but not yet fulfilled. An
increase or decrease in the order backlog corresponds to the order
intake of the reporting period, net of invoiced services, completed
or cancelled contracts, and currency impact for projects in foreign
currency (re-evaluated at the exchange rate on closing date).
Orders are booked once the customer confirms, in writing, its
retention of the Company’s services for a given project. The
contract is usually signed a few months after written
confirmation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230119005545/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ggasparetto@actifin.fr
Median Technologies (EU:ALMDT)
過去 株価チャート
から 2 2024 まで 3 2024
Median Technologies (EU:ALMDT)
過去 株価チャート
から 3 2023 まで 3 2024